Jele Chemists Pty Ltd v Australian Community Pharmacy Authority

Link copied
Case Copied 56 min read

FEDERAL COURT OF AUSTRALIA

Jele Chemists Pty Ltd v Australian Community Pharmacy Authority [2025] FCAFC 54

Appeal from: Jele Chemists Pty Ltd v Australian Community Pharmacy Authority [2023] FCA 1652
File number: QUD 47 of 2024
Judgment of: COLLIER ACJ, ROFE AND HORAN JJ
Date of judgment: 15 April 2025
Catchwords: ADMINISTRATIVE LAW – proper construction of s 10(3)(c) of National Health (Australian Community Pharmacy Authority Rules) Determination 2018 (Cth) (National Health Rules) – whether development approval under Planning Act 2016 (Qld) is required to be in effect for Australian Community Pharmacy Authority (ACPA) to make recommendation to Secretary of Department of Health and Aged Care (Secretary) – whether ACPA required to engage with local government and State or Territory planning laws – whether institution of appeal of development approval means premises unable to be used for operation of pharmacy “at all relevant times” – whether recommendation of ACPA only possible in relation to physical premises – whether “proposed premises” means physical premises – whether measurement between two premises requires existence of two physical premises – s 8 and sch 1, pt 2, item 130 of National Health Rules – appeal dismissed
Legislation:

Administrative Decisions (Judicial Review) Act 1977 (Cth) ss 5(1)(f), 5(1)(h)

Judiciary Act 1903 (Cth) s 79

National Health Act 1953 (Cth) ss 90, 99K, 99L, 99N

National Health (Australian Community Pharmacy Authority Rules) Determination 2018 (Cth) ss 5, 8(1), 10(1)(b)(ii), 10(2)(b)(ii), 10(3)(c), sch 1, pt 2, item 130

Integrated Planning Act 1997 (Qld) s 3.5.19

Planning Act 2016 (Qld) s 71

Cases cited:

Assarapin v Australian Community Pharmacy Authority (2016) 239 FCR 161; [2016] FCAFC 9

Graham v Minister for Immigration and Border Protection (2017) 263 CLR 1

Hayes v Walker (2004) 134 LGERA 290; [2004] QCA 288

Hossain v Minister for Immigration and Border Protection (2018) 264 CLR 123

Jele Chemists Pty Ltd v Australian Community Pharmacy Authority [2023] FCA 1652

R v Connell; Ex parte Hetton Bellbird Collieries Ltd (1944) 69 CLR 407

Shrestha v Minister for Immigration and Border Protection (2018) 264 CLR 151

Te v Minister for Immigration and Ethnic Affairs (1999) 88 FCR 264

Terry White Chemists Australia Fair v Secretary to the Department of Health and Ageing (2009) 178 FCR 161; [2009] FCAFC 74

Watson v Australian Community Pharmacy Authority (2012) 206 FCR 365

Division: General Division
Registry: Queensland
National Practice Area: Administrative and Constitutional Law and Human Rights
Number of paragraphs: 72
Date of hearing: 21 August 2024
Counsel for the Appellant: Mr C Gunson SC with Dr A McBeth
Solicitor for the Appellant: Robert James Lawyers
Counsel for the First Respondent: Ms K E Slack
Solicitor for the First Respondent: Sparke Helmore Lawyers
Counsel for the Second Respondent: The Second Respondent filed a submitting notice, save as to costs
Counsel for the Third Respondent: Mr T Flaherty
Solicitor for the Third Respondent: Michael Flaherty Solicitor

ORDERS

QUD 47 of 2024
BETWEEN:

JELE CHEMISTS PTY LTD (ACN 651 116 666)

Appellant

AND:
CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Jele Chemists Pty Ltd v Australian Community Pharmacy Author... and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2025] FCAFC 54
Decision Date

CaseChat Overview and Summary

Jele Chemists Pty Ltd sought to appeal against a decision of the primary Judge, who dismissed their further amended originating application. The appeal was against the Australian Community Pharmacy Authority, with the Secretary of the Department of Health and Aged Care as a party of interest. The dispute related to the interpretation and application of certain provisions in the National Health (Australian Community Pharmacy Authority Rules) Determination 2018 (Cth) (National Health Rules) and the Planning Act 2016 (Qld). Specifically, the issues included whether development approval under the Planning Act was required to be in effect for the Authority to make a recommendation to the Secretary, whether the Authority needed to engage with local government and State or Territory planning laws, and whether the institution of an appeal of development approval meant the premises could not be used for the operation of a pharmacy at all relevant times. The court needed to decide these issues to determine the validity of the Authority's recommendation and the Secretary's subsequent approval of a pharmacy application.

The court's reasoning focused on the proper construction of the relevant provisions of the National Health Rules and the legislative framework governing pharmacy approvals. The primary Judge had correctly interpreted the provisions, and the Full Court found no error in her Honour's reasoning. The court held that there was no requirement for final development approval to be in effect before the Authority could make a recommendation. The court also clarified that compliance with relevant local government and State or Territory planning laws was a factor for consideration, but not an absolute requirement. The court found that the primary Judge's interpretation of the provisions was consistent with the object of the legislation, which was to establish and regulate the provision of drugs and medicinal preparations on a subsidised basis. The court further held that the Secretary was not required to engage in an onerous procedure involving duplication of functions by considering every provision of State or Territory law that might bear on the legality of conducting a pharmacy business.

The appeal was dismissed, and the appellant was ordered to pay the costs of the third respondent of and incidental to the appeal, to be taxed if not otherwise agreed. This outcome upheld the primary Judge's decision and affirmed the correct interpretation and application of the relevant provisions in the National Health Rules and the Planning Act.

Orders

Orders of the court

1. The appeal be dismissed.

2. The appellant pay the costs of the third respondent of and incidental to the appeal, to be taxed if not otherwise agreed.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

The primary Judge dismissed the further amended originating application.BACKGROUND The primary Judge helpfully summarised relevant background to the proceedings as follows:22On 24 August 2021, a development application was lodged with the Toowoomba Regional Council for a Material Change of Use – Health Care Services (Medical Centre) and Shop (Pharmacy) in connection with the Glenvale Premises (Development Application).23In November 2021, submissions were made to the Council as part of the public notification phase of the Development Application.24On 1 April 2022, the Council issued a Decision Notice approving the Development Application, and on 14 April 2022 it issued letters to those who made submissions to it during the public notification phase advising of the decision and providing details of appeal rights.25On 12 April 2022, the applicant lodged an application with the Minister for Health and Aged Care to exercise his power pursuant to s 90A(2) of the [National Health Act] to approve the supply of pharmaceutical benefits (Applicant’s Application) at the property located at Shop 2, Glenvale Shopping Centre, Toowoomba Queensland 4350 (Applicant’s Premises). The background to this application is a preceding application made by the applicant on 16 December 2021 pursuant to Sch 1, Pt 2, Item 30 of the Rules for approval to supply pharmaceutical benefits from the Applicant’s Premises, which was rejected on 17 February 2022 as the Authority was not satisfied that the Applicant’s Premises were located at least 1.5 km, in a straight line, from the nearest approved premises.26On 20 April 2022, Glenvale Pharmacy lodged an application pursuant to Sch 1, Pt 2, Item 130 of the Rules for approval to supply pharmaceutical benefits from the Glenvale Premises (Glenvale Pharmacy’s Application). The Glenvale Premises are located within 300 metres in a straight line from the Applicant’s Premises.27On 28 April 2022, solicitors for the applicant sent an email to the “Ministerial Discretion Team” of the Department of Health asking to be notified of any application to establish a new pharmacy and/or to relocate an existing pharmacy within 5 kilometres of the Glenvale Premises for the purposes of making comments on such applications as an interested party.28On 2 May 2022, the applicant was notified of Glenvale Pharmacy’s Application.29On 10 May 2022, an appeal was lodged by Stokes Lawyers, who acted for the applicant some time prior to these proceedings, with the Planning and Environment Court against the Council’s approval of the Development Application. Final orders were made on 9 June 2022 granting leave to discontinue the appeal.30On 11 May 2022 the applicant objected to Glenvale Pharmacy’s Application to the Authority on the basis that, at all relevant times, the Glenvale Premises could not be used to operate a pharmacy under applicable local government and State and Territory laws relating to land development, because the Council's decision to approve the Development Applicant [sic] had been the subject of an appeal to the Planning and Environment Court.31On 15 July 2022, the Authority recommended that Glenvale Pharmacy’s Application be approved. Notification of that was sent to Glenvale Pharmacy on 18 July 2022, and to the applicant on 1 August 2022. On 3 August 2022, the applicant requested a statement of reasons from the Authority.32On 10 August 2022, the applicant wrote to the Secretary seeking written confirmation, within 10 days of the date of its letter, that the Secretary had decided to reject the Authority’s recommendation on the basis of their “irrefutable contention” that Glenvale Premises at all relevant times could not be used for the operation of a pharmacy pursuant to r 10(3) of the Rules.33On 19 August 2022, the Secretary responded to the applicant advising that he would consider the matters raised in its objection when making a decision as to whether or not approval would be granted to Glenvale Pharmacy, and otherwise stated that if it was dissatisfied with the Authority’s recommendation, it was a matter for the applicant as to whether it commenced judicial review proceedings.34 On 29 August 2022, the applicant commenced this proceeding.35The Authority provided its statement of reasons on 31 August 2022 which stated, inter alia, that it was satisfied at all relevant times that Glenvale Premises could be used to operate a pharmacy under applicable local government and State and Territory laws relating to land development.36The applicant then, on 6 September 2022, sought an undertaking from the Secretary that he would refrain from making a decision with respect to Glenvale Pharmacy’s Application while proceedings were before the Court. The Secretary declined to provide such an undertaking but agreed to give the applicant seven days' notice prior to making a decision with respect to Glenvale Pharmacy's Application.37On 11 October 2022, the Applicant’s Application was approved by the Minister, effective from 4 October 2022.38On 21 November 2022, the applicant was advised by the Secretary that he would be considering Glenvale Pharmacy’s Application on or after 1 December 2022. The applicant sought an undertaking from Glenvale Pharmacy that it would refrain from opening the pharmacy on the Glenvale Premises while these proceedings were on foot, and that it would refrain from seeking approval from the Secretary for the Glenvale Premises, which undertaking Glenvale Pharmacy refused to provide.39On 25 November 2022, the applicant filed an interlocutory application in this proceeding seeking that the Secretary be restrained from approving Glenvale Pharmacy’s Application. The Court dismissed the application, finding that ground 1(a) (defined below) did not constitute a serious question to be tried and sought to conflate merits review with judicial review and that, in any event, the balance of convenience did not weigh in favour of the applicant: Jele Chemists Pty Ltd v Australian Community Pharmacy Authority [2022] FCA 1445 at [19], [29] (Collier J).40On 8 December 2022, a delegate of the Secretary approved Glenvale Pharmacy’s Application. 41Thereafter, Glenvale Pharmacy commenced trading from the Glenvale Premises around 15 December 2022 and the applicant commenced trading from the Applicant’s Premises on 6 February 2023…(emphasis in original)

Evidence

Evidence Before The Court

Decision

Reasons for decision

COLLIER ACJ

Ratio Decidendi

Legal Principle Established

Established by: COLLIER ACJ

In relation to ground of appeal 2, the third respondent further submitted, in summary that:·The use of the modifier “proposed” with respect to premises indicates that premises can be under construction or planned to be built, provided that their proposed location is readily ascertainable.·In any event, proposed premises, whether unbuilt, partially constructed or built could not “lawfully be used” as a pharmacy without full and final development approval, as well as having been stocked, fitted out and obtained the approval of the relevant State pharmacy bodies.CONSIDERATION We have already set out in some detail relevant legislative provisions, and the primary Judge’s reasons for judgment interpreting those provisions. Importantly, for the purposes of this appeal, pursuant to s 90 of the National Health Act (where a pharmacist applies for approval to supply pharmaceutical benefits from particular premises) the Secretary must refer the application to ACPA. In considering an application referred to it by the Secretary, ACPA must comply with the National Health Rules: s 99K of the National Health Act. The Secretary may only approve an application if ACPA has recommended the application for approval: s 90(3B) of the National Health Act. In our view, the primary Judge correctly construed the provisions of the National Health Act and the National Health Rules. Her Honour’s decision should be upheld. We have formed this view for the following reasons. First, as the primary Judge correctly found, there is no requirement that a final development approval for the operation of a pharmacy at the proposed premises be in effect before ACPA can make a recommendation for approval by the Secretary. Section 10(3)(c) of the National Health Rules plainly provides that a recommendation can be made if (inter alia) at all relevant times a proposed premises could be used for the operation of a pharmacy under applicable planning laws. In the present case, as ACPA noted in its decision, a Development Application Decision Notice dated 1 April 2022 was issued by the Toowoomba Regional Council approving the Material Change of Use of the proposed premises to “Health Care Service and Shop”. As the primary Judge further observed, the Note to s 10(3) of the National Health Rules makes clear that final effective development approval is unnecessary. In particular, reference should be made to the statement in the Note that s 10(3)(c) would be satisfied if “the proposed premises are on land that is zoned so as to enable the operation of a pharmacy”. The interpretation of s 10(3)(c) applied by the primary Judge is consistent with earlier authority. It is not in doubt that compliance with relevant local government and State or Territory planning laws is a factor for consideration, by both ACPA and ultimately the Secretary, in respect of pharmacy approvals. However, as the Full Court observed in Terry White Chemists in respect of an earlier (but comparable) iteration of s 90(1) of the National Health Act, the object of the legislation in respect of applications for approval to conduct the operation of a pharmacy at proposed premises:19.…is to establish and regulate the provision of drugs and medicinal preparations to members of the public for whom they are prescribed, on a subsidised basis. It is unlikely that, in the pursuit of a purpose associated with that scheme, Parliament would have intended to require the Secretary to search for and consider every provision of the law of the State or Territory in which the relevant premises were situated that might bear on the legality of the person applying for approval conducting the business of a pharmacist at those premises. Not only would the task of ascertaining what were the relevant provisions be onerous, the process of applying them would involve duplication of functions that are already committed to the authorities of the State or Territory concerned. It is unlikely that Parliament intended that such duplication should occur. The rights and wrongs of the conduct of particular activities at particular premises are matters for the concern of State and Territory authorities, and not for the concern of the Secretary. A construction that requires the Secretary to engage in an onerous procedure, involving duplication of functions, should not be adopted if there is an alternative construction that promotes the purpose or object of the provisions. To the extent to which it might be considered that State or Territory laws are relevant, it is open to the Minister to make rules pursuant to s 99L of the National Health Act, requiring the Authority to apply those laws as part of its consideration of an application for approval referred to it under s 90(3A) of the National Health Act.(emphasis added)